Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 20/20 | 0.72 |
| ▸ | CCR3 | P51677 | 20/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 17/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6242779 | 0.88 | HRH1 (0.72) | HRH1CCR3KCNH2 | |
| SCHEMBL5191284 | 0.88 | HRH1 (0.65) | HRH1CCR3KCNH2 | |
| SCHEMBL5190493 | 0.87 | HRH1 (0.67) | HRH1CCR3KCNH2 | |
| SCHEMBL5194584 | 0.86 | HRH1 (0.66) | HRH1CCR3KCNH2 | |
| SCHEMBL5194600 | 0.85 | HRH1 (0.64) | HRH1CCR3KCNH2 | |
| SCHEMBL5194856 | 0.84 | HRH1 (0.77) | HRH1CCR3KCNH2 | |
| SCHEMBL5190333 | 0.84 | HRH1 (1.00) | HRH1CCR3KCNH2 | |
| SCHEMBL5190415 | 0.84 | HRH1 (0.74) | HRH1CCR3KCNH2 | |
| Pivalate SCHEMBL6244884 | 0.84 | HRH1 (0.70) | HRH1CCR3KCNH2 | |
| SCHEMBL5191226 | 0.84 | HRH1 (0.74) | HRH1CCR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1816123-A1 | Intermediates for the production of pharmaceutically active compounds | AstraZeneca AB (SE) | 2007-08-08 | — | — | EP | disclosed |
| EP-1546130-B1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASE STATES | ASTRAZENECA AB (SE) | 2007-08-01 | — | — | EP | disclosed |
| US-20060040984-A1 | Novel piperidine derivatives for use in the treatment of chemokine medicated disease states | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | US | disclosed |
| EP-1546130-A1 | NOVEL PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASE STATES | AstraZeneca AB (SE) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004029041-A1 | NOVEL PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASE STATES | ASTRAZENECA AB (SE) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040984-A1 | Novel piperidine derivatives for use in the treatment of chemokine medicated disease states | CCR3, CCR1, CCL11 | HRH1 49/4885CCR3 1/4885KCNH2 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.